...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells.
【24h】

Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells.

机译:骨相关生长因子和唑来膦酸调节MG-63人骨肉瘤细胞中的PTHrP / PTH.1受体生物调节系统。

获取原文
获取原文并翻译 | 示例

摘要

Bisphosphonates are known to inhibit osteoclast-mediated bone resorption and osteoblast differentiation and are currently used in the treatment of Paget's disease, osteoporosis, metastatic and osteolytic bone disease and hypercalcaemia of malignancy. The parathyroid hormone-related peptide (PTHrP) and type 1 PTH/PTHrP receptor (PTH.1R) bioregulation systems mediate a wide range of local paracrine/autocrine and intracrine functions in various tissues and modify the actions of pharmaceutical agents on target tissues, both in vivo and in vitro. In addition, bone microenvironment-related growth factors, such as insulin-like growth factor 1 (IGF-1), transforming growth factor beta 1 (TGF beta 1), basic fibroblast growth factor (bFGF) and interleukin 6 (IL-6), can modify the actions of various pharmaceutical agents, including cytotoxic drugs in malignant cell lines. Whether IGF-1, TGF beta 1, bFGF, IL-6 and zoledronic acid affect the expressions of PTHrP and PTH.1R in MG-63 osteoblast-like osteosarcoma cellswas investigated in this study. Relative quantitative-PCR (expression at mRNA level) and immunofluorescence analysis (localization of the expression at protein level) were employed to assess PTHrP and PTH.IR expressions. Our data showed that primarily IGF-1, TGF beta 1 and IL-6 (up to 25 ng/ml for 48 h) increased PTHrP mRNA expression and modified its perinuclear localization, while zoledronic acid (up to 100 microM for 48 h) inhibited cell proliferation and suppressed PTHrP expression in the MG-63 osteosarcoma cells. These growth factors were incapable of reversing the zoledronic acid decrease of the expression of PTHrP in the MG-63 cells, suggesting that zoledronic acid and the growth factors affect PTHrP expression via an independent intracellular signal transduction pathway in these cells. However, no appreciable modulation of the PTH.1R expression by IGF-1, TGF beta 1, bFGF, IL-6 or zoledronic acid was detected in MG-63 cells. Therefore, we conclude that PTHrP expression possibly mediates the action of bone microenvironment-related growth factors and of zoledronic acid in MG-63 cells.
机译:已知双膦酸盐可抑制破骨细胞介导的骨吸收和成骨细胞分化,目前已用于治疗Paget病,骨质疏松症,转移性和溶骨性骨病以及恶性高钙血症。甲状旁腺激素相关肽(PTHrP)和1型PTH / PTHrP受体(PTH.1R)生物调节系统介导各种组织中广泛的局部旁分泌/自分泌和内分泌功能,并改变药剂对靶组织的作用体内和体外。此外,骨骼微环境相关的生长因子,如胰岛素样生长因子1(IGF-1),转化生长因子beta 1(TGF beta 1),碱性成纤维细胞生长因子(bFGF)和白介素6(IL-6)可以改变各种药剂的作用,包括恶性细胞系中的细胞毒性药物。研究IGF-1,TGFβ1,bFGF,IL-6和唑来膦酸是否影响MG-63成骨细胞样骨肉瘤细胞中PTHrP和PTH.1R的表达。使用相对定量PCR(在mRNA水平上的表达)和免疫荧光分析(在蛋白水平上的表达定位)来评估PTHrP和PTH.IR表达。我们的数据显示,主要是IGF-1,TGF beta 1和IL-6(48 h时高达25 ng / ml)增加了PTHrP mRNA的表达并改变了其核周定位,而唑来膦酸(48小时时高达100 microM)抑制MG-63骨肉瘤细胞中细胞增殖并抑制PTHrP表达。这些生长因子不能逆转唑来膦酸在MG-63细胞中PTHrP表达的降低,表明唑来膦酸和生长因子通过这些细胞中独立的细胞内信号转导途径影响PTHrP表达。但是,在MG-63细胞中未检测到IGF-1,TGFβ1,bFGF,IL-6或唑来膦酸对PTH.1R表达的明显调节。因此,我们得出结论,PTHrP表达可能介导MG-63细胞中骨微环境相关的生长因子和唑来膦酸的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号